PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
Site Search
Showing 1 - 10 of 13 results
News
|
March 2, 2009
|
1 min read
News
|
Aug. 1, 2008
|
1 min read
News
|
Aug. 11, 2014
|
2 min read
News
|
Feb. 15, 2007
|
2 min read
News
|
Aug. 11, 2014
|
1 min read
News
|
Dec. 28, 2007
|
1 min read
News
|
March 3, 2017
|
3 min read
Cystic fibrosis affects people of every racial and ethnic group. Of the nearly 40,000 people living with CF in the U.S., approximately 15% are identified as racially or ethnically diverse. Research shows that people of color with CF, particularly people who are Black and Hispanic, experience unique challenges and often have negative experiences that can lead to poorer outcomes. Some of these inequities are referenced in the following data.
4 min read
The Foundation seeks to advance its mission by making improvements in key areas of health equity and outcomes and diverse workforce development.
News
|
Feb. 15, 2023
|
3 min read
The Foundation’s commitment to these principles will continue to be a cornerstone of the Foundation’s work to advance our mission in 2023.
News
|
Jan. 19, 2023
|
4 min read